Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.

Hanauer JDS, Rengstl B, Kleinlützum D, Reul J, Pfeiffer A, Friedel T, Schneider IC, Newrzela S, Hansmann ML, Buchholz CJ, Muik A.

Oncotarget. 2018 Jan 12;9(16):12971-12981. doi: 10.18632/oncotarget.24191. eCollection 2018 Feb 27.

2.

Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective.

Kleinlützum D, Hanauer JDS, Muik A, Hanschmann KM, Kays SK, Ayala-Breton C, Peng KW, Mühlebach MD, Abel T, Buchholz CJ.

Front Oncol. 2017 Jun 26;7:127. doi: 10.3389/fonc.2017.00127. eCollection 2017.

3.

Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.

Liu YP, Steele MB, Suksanpaisan L, Federspiel MJ, Russell SJ, Peng KW, Bakkum-Gamez JN.

Gynecol Oncol. 2014 Jan;132(1):194-202. doi: 10.1016/j.ygyno.2013.11.010. Epub 2013 Nov 15.

4.

Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins.

Ayala-Breton C, Barber GN, Russell SJ, Peng KW.

Hum Gene Ther. 2012 May;23(5):484-91. doi: 10.1089/hum.2011.146. Epub 2012 Feb 7.

5.

Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.

Betancourt D, Ramos JC, Barber GN.

J Virol. 2015 Dec;89(23):11786-800. doi: 10.1128/JVI.01356-15. Epub 2015 Sep 16.

6.

Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Wollmann G, Drokhlyansky E, Davis JN, Cepko C, van den Pol AN.

J Virol. 2015 Jul;89(13):6711-24. doi: 10.1128/JVI.00709-15. Epub 2015 Apr 15.

7.

Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.

Eberle FC, Song JY, Xi L, Raffeld M, Harris NL, Wilson WH, Pittaluga S, Jaffe ES.

Am J Surg Pathol. 2012 May;36(5):716-25. doi: 10.1097/PAS.0b013e3182487158.

8.

Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.

Janelle V, Brassard F, Lapierre P, Lamarre A, Poliquin L.

J Virol. 2011 Jul;85(13):6513-20. doi: 10.1128/JVI.02484-10. Epub 2011 May 11.

9.

Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.

Makita S, Maeshima AM, Taniguchi H, Kitahara H, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Kobayashi Y, Tobinai K.

Int J Hematol. 2016 Sep;104(3):396-9. doi: 10.1007/s12185-016-2018-y. Epub 2016 May 12.

PMID:
27169615
10.

Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.

Gharbaran R, Goy A, Tanaka T, Park J, Kim C, Hasan N, Vemulapalli S, Sarojini S, Tuluc M, Nalley K, Bhattacharyya P, Pecora A, Suh KS.

J Hematol Oncol. 2013 Aug 29;6:62. doi: 10.1186/1756-8722-6-62.

11.

Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus.

Ayala-Breton C, Russell LO, Russell SJ, Peng KW.

J Virol. 2014 Aug;88(15):8332-9. doi: 10.1128/JVI.03823-13. Epub 2014 May 14.

12.

Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.

Wu Y, Lun X, Zhou H, Wang L, Sun B, Bell JC, Barrett JW, McFadden G, Biegel JA, Senger DL, Forsyth PA.

Clin Cancer Res. 2008 Feb 15;14(4):1218-27. doi: 10.1158/1078-0432.CCR-07-1330.

13.

Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.

Patel MR, Jacobson BA, Ji Y, Drees J, Tang S, Xiong K, Wang H, Prigge JE, Dash AS, Kratzke AK, Mesev E, Etchison R, Federspiel MJ, Russell SJ, Kratzke RA.

Oncotarget. 2015 Oct 20;6(32):33165-77. doi: 10.18632/oncotarget.5320.

14.

The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.

Janelle V, Langlois MP, Lapierre P, Charpentier T, Poliquin L, Lamarre A.

Mol Ther. 2014 Jun;22(6):1198-1210. doi: 10.1038/mt.2014.34. Epub 2014 Mar 4.

15.

Optimized Lentiviral Transduction Protocols by Use of a Poloxamer Enhancer, Spinoculation, and scFv-Antibody Fusions to VSV-G.

Anastasov N, Höfig I, Mall S, Krackhardt AM, Thirion C.

Methods Mol Biol. 2016;1448:49-61. doi: 10.1007/978-1-4939-3753-0_4.

PMID:
27317172
16.

Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.

Naik S, Nace R, Barber GN, Russell SJ.

Cancer Gene Ther. 2012 Jul;19(7):443-50. doi: 10.1038/cgt.2012.14. Epub 2012 Apr 20.

17.

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, Kottke T, Barber GN, Melcher A, Vile RG.

Hum Gene Ther. 2010 Apr;21(4):439-50. doi: 10.1089/hum.2009.143.

18.

Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.

Capo-chichi CD, Yeasky TM, Heiber JF, Wang Y, Barber GN, Xu XX.

Gynecol Oncol. 2010 Feb;116(2):269-75. doi: 10.1016/j.ygyno.2009.10.086. Epub 2009 Nov 22.

19.

Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.

Hristodorov D, Nordlohne J, Mladenov R, Huhn M, Fischer R, Thepen T, Barth S.

Br J Haematol. 2014 Jan;164(2):251-7. doi: 10.1111/bjh.12626. Epub 2013 Oct 25.

PMID:
24164493
20.

Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.

Ayala-Breton C, Suksanpaisan L, Mader EK, Russell SJ, Peng KW.

Mol Ther. 2013 Oct;21(10):1930-7. doi: 10.1038/mt.2013.164. Epub 2013 Jul 11.

Supplemental Content

Support Center